Penumbra, Inc.
PEN · Price history
Price at last available close
$318.31
−$0.87 (-0.27%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Penumbra, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
How they make money
Penumbra generates revenue primarily through the design, development, manufacture, and marketing of innovative medical devices for thrombectomy procedures. The company sells its products globally to hospitals and clinics, where they are used by specialist physicians to treat challenging medical conditions such as ischemic stroke, pulmonary embolism, and acute limb ischemia.
Products & services
The company offers a portfolio of mechanical thrombectomy devices, including the Penumbra System Reperfusion Catheters, which are powered by the Penumbra ENGINE or Penumbra Pump MAX to facilitate thrombus removal.
Brands & revenue mix
The company's primary brand of mechanical thrombectomy products used for revascularization.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Third-party information technology and network service providers — Providers of systems used to manage business processes, including sales, billing, marketing, procurement, supply chain, manufacturing, and distribution.Source
Strengths
- Proprietary processes and materials science innovations in catheter designSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
45
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
84
Strong
Financial Strength
82
Business Quality / Moat
99
Management
100
Growth Quality
54
Risk / Durability
64
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
24
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
35/100
Building Historical Record
Model Score 35/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for PEN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can PEN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is PEN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does PEN's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify PEN's current valuation?
Essential Investment Snapshot
Wall Street Score
45
Opportunity Score
24
Market Cap
$12.54B
P/E Ratio
78.3
EPS
$4.09
52-Week High
$362.41
52-Week Low
$221.26
Beta
0.70
Intrinsic Value
$157.47
Analyst Target
$320.00
Shares Outstanding
39.3M
Total Revenue
$1.50B
Total Debt
$212.7M
Dividend
No current dividend
Liquidation Value / Share
$38.96
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on PEN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary processes and materials science innovations in catheter design.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Reliance on third-party information technology, networks, and systems.
- −Inability to achieve or maintain satisfactory pricing and margins.
- −Manufacturing difficulties and potential product defects or failures.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
45
Oct 1, 2026
Change
-0.1
points
Current Score
45
Oct 12, 2026
Category Changes
PEN decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
42
Projected Change
-3.6 points
Preliminary comparable-period financial changes suggest decline of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$318.31
Model Intrinsic Value
$157.47
Difference
+$160.84
+102.1% vs IV
Margin of Safety
-102.1%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.50B | $1.40B | $1.19B | $1.06B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $484.0M | $461.2M | $439.6M | $375.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.02B | $942.4M | $755.0M | $682.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $92.2M | $89.8M | $94.8M | $84.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $741.3M | $663.4M | $574.0M | $506.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $833.6M | $753.2M | $668.8M | $609.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $222.3M | $223.9M | $46.0M | $108.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $187.3M | $189.2M | $86.2M | $73.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.3M | $1.3M | $1.4M | $1.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $203.8M | $205.1M | $20.9M | $79.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $43.2M | $27.4M | $6.9M | -$11.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $160.6M | $177.7M | $14.0M | $91.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $4.09 | $4.57 | $0.36 | $2.37 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 39.31M | 38.92M | 38.63M | 38.40M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 39.57M | 39.29M | 39.27M | 39.22M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$390.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.88
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-3.5%
Cash Change
-51.3%
Margin Change
-4.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels. Pressure indicators included EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 14.9%. EPS declined 23.5%. Cash declined 51.3%. Total debt declined 3.5%. Net income margin declined by 4.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
7
Smart Money
7
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
IART vs. PEN: Which Stock Is the Better Value Option?
Rumor Mill · PEN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial